Novartis

Novartis is a multinational pharmaceutical company that appears across elsewhere's coverage as a major dealmaker in biotech and radiopharma. In 2019 it acquired Endocyte's Pluvicto project for $2.1 billion, a transaction that helped trigger the targeted radiotherapy boom . The company's Zolgensma, an AAV9-based gene therapy for spinal muscular atrophy approved in 2019, remains one of the most prominent approved gene therapies globally . More recently, in July 2025, Vitairolin granted Novartis an exclusive option to acquire its proprietary brain delivery platform in a deal carrying $175 million in upfront and near-term payments , and in early 2026 Zhongsheng Quanpeptide licensed peptide pipeline assets to Novartis alongside Eli Lilly, with combined upfront payments nearing $70 million . Elsewhere's corpus does not cover Novartis's founding or headquarters details.